Publication | Open Access

Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment

Hematological MalignancyCancer ImmunosurveillanceMultiple Myeloma TreatmentImmunologyImmune Checkpoint InhibitorAutoimmunityTarget ExpressionImmunotherapyMedicineCell BiologyPreclinical Activity